University of Pennsylvania Health System - PCAM, Dept. of Rheumatology
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Neubauer, Robin
NCT05526989: Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Recruiting
2
25
US
Dostarlimab, Jemperli, Niraparib, Zejula
H. Lee Moffitt Cancer Center and Research Institute, GlaxoSmithKline
Penile Carcinoma
11/26
11/27
NUV-868-01, NCT05252390: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Recruiting
1/2
657
US, RoW
NUV-868, Olaparib, Lynparza, Enzalutamide, Xtandi
Nuvation Bio Inc.
Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
06/26
11/26
KOAR, NCT03326076: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

Active, not recruiting
N/A
4000
US
Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
CareDx
Kidney Transplant Rejection
06/25
12/25
Sandorfi, Nora
NEPTUNUS-2, NCT05349214 / 2021-005687-22: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Active, not recruiting
2/3
301
Europe, Japan, US, RoW
HZN-825 BID, Placebo, HZN-825 QD
Amgen, Horizon Therapeutics USA, Inc
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
09/25
09/25
CONQUEST, NCT06195072: Platform Clinical Study for Conquering Scleroderma

Recruiting
2
400
US
Amlitelimab, BI 1015550, Placebo
Scleroderma Research Foundation, Inc., Sanofi, Boehringer Ingelheim
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
11/26
11/26

Download Options